Malignant pheochromocytomas are rare, accounting for ∼10% of all cases of pheochromocytoma. The prognosis is poor because of local recurrence or widespread metastasis [1] . To date, there has been no established chemotherapy for malignant pheochromocytoma. A conventional CVD regimen (consisting of cyclophosphamide, vincristine and dacarbazine) may reduce tumors, but remission is short [2] . Thus, attempts to devise other regimens are warranted in order to obtain a better outcome.
We report a 50-year-old Japanese male who had rapidly progressive malignant pheochromocytoma and was successfully treated with an ACVD regimen, anthracyclines plus CVD. The patient was diagnosed with left adrenal pheochromocytoma (4 × 3 cm) with increased catecholamine (CA) excretion levels and underwent adrenectomy in August 1990. He had become asymptomatic and CA excretion level dropped to normal after the surgery. Six years later, he presented with lower back pain, soaking sweats and right inguinal lymphadenopathy. CAs and their metabolites were elevated (Table 1) . A CT (computed tomography) scan showed enlarged lymph nodes in the pelvic and para-aortic region. Biopsy specimens of the inguinal lymph node revealed relapse of the pheochromocytoma. Subsequently, the right inguinal lymph node enlarged from 2 to 10 cm in ∼2 weeks, and the back pain was aggravated.
In February 1996, a combination chemotherapeutic regimen was initiated, consisting of doxorubicin 40 mg/m 2 body surface area (BSA) on day 1, cyclophosphamide 750 mg/m 2 BSA on day 1, vincristine 1.4 mg/m 2 BSA on day 1 and dacarbazine 250 mg/ m 2 BSA on days 1-5, every 3-4 weeks. On the following day, the blood pressure dropped to 90/56 mm Hg. With i.v. hydration increased, his general condition improved within a few days. Symptoms were resolved over 2 weeks with normalization of CAs and their metabolites ( Table 1 ). Since cardiovascular instability occurred, doxorubicin was replaced with epirubicin, which has lower cardiotoxicity, in the later chemotherapy. The patient was given 12 courses of ACVD combination chemotherapy, which led to a complete remission of the tumor and a biochemical response. Side-effects were grade 1 bone marrow suppression, nausea and hair loss. After February 1997, the consolidation CVD regimen was administered monthly for ∼3 years. There has been no sign of recurrence for 3 years after the cessation of chemotherapy.
Considering their neural crest origin and biological similarities, the chemotherapeutic regimens for neuroblastoma could be promising candidates for malignant pheochromocytoma. The CVD regimen was based on the treatment for advanced neuroblastoma. This regimen has been reported to produce good responses in malignant pheochromocytoma, but the median duration of remis- sion is 21 months [2] . For aggressive neuroblastoma, a combination chemotherapeutic regimen of cyclophosphamide, vincristine, dacarbazine and doxorubicin (CYVADIC) has been suggested to be more effective than doxorubicin alone or combination therapy without doxorubicin (CYVDIC) [3] . We achieved long-lasting complete remission using a ACVD regimen in a case with rapidly progressive disease. To our knowledge, this is the first report of an anthracyclinecontaining combination chemotherapy for metastasized malignant pheochromocytoma. The ACVD regimen might be a feasible combination chemotherapy, with monitoring of the cardiovascular system; furthermore, it might improve response rates and lengthen disease-free survival. First, one can note that the four laboratory variables that were of independent prognostic significance in Koehne et al.'s multivariate analysis were the four with the lowest percentages of missing data, i.e. 30% for WBC or haemoglobin, 32% for platelets, and 38% for ALP, compared with 72% for LDH, 67% for albumin, 53% for CEA, 46% for bilirubin, and 48% and 44% for the aminotransferases. This might have flawed their analysis.
Secondly, a number of other studies have used multivariate statistical analysis to compare the prognostic values of ALP or WBC with those of one or several of the other afore-mentioned laboratory variables. The many studies published so far, taking into account only overall survival (the objective outcome), include: Fountzilas et al.'s study in which CEA or albumin were of independent significance, whereas WBC, ALP or LDH were not [2] ; Saltz et al.'s study in which LDH, bilirubin, WBC or haemoglobin were of independent significance, whereas CEA was not [3] ; and Steinberg et al.'s study in which albumin or aspartate aminotransferase were of independent significance, whereas ALP was not [4] . These examples are a short summary of the quite contradictory results that have been published so far on the subject (a list of other references is available from us on request).
In order to explain such controversial results, various hypotheses have been proposed, among these the likely heterogeneity in the laboratory techniques used in these numerous studies deserves a mention. The problem is that, as far as we know, none of the studies published so far clearly indicated its laboratory methods. In this situation, it would not be possible for independent teams to try to precisely reproduce the laboratory techniques used in these studies-a basic principle of good science. Some of the problems that may be caused by this situation are quite well established; in particular, for some laboratory variables, randomly distributed variations of >50% from one study to another, can not be excluded [5] .
In summary, Koehne et al. suggested that in order to stratify metastatic colorectal cancer patients in clinical trials, one would have to measure ALP, WBC, haemoglobin and platelets. Taking into account the other studies published so far (i.e. evidence-based laboratory medicine) would suggest that at least LDH, transaminases, bilirubin, albumin and CEA should be added to this list of laboratory variables that should be mandatory to measure. Also, the laboratory methodologies should be indicated in any ensuing publication in order to eventually make it possible to better establish not only the most useful laboratory tests in this context, but also the best way to measure them.
